Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Eur J Cancer. 2018 Jan 12;91:68–75. doi: 10.1016/j.ejca.2017.12.018

Figure 2.

Figure 2

Cost-effectiveness results for women vaccinated against HPV infections with the nonavalent vaccine (9vHPV). Efficient strategies are accentuated with a larger symbol and connected by the solid line (i.e. efficiency frontier). Parentheses for the efficient strategies indicate screening frequency (e.g. “20-yearly” or “1x/2x” indicate one or two lifetime screens) and age to start screening. All costs are expressed in 2014 Euros (EUR€ = NOK8.35).

Abbreviations: HPV, human papillomavirus; QALY, quality-adjusted life-years.